polymorphism
The association between the lncRNA GAS5 rs145204276 indel polymorphism and cancer risk is presented in Table 2. The pooled OR of the ten relevant studies for different genetic models was elucidated.
There was no significant association between the lncRNA GAS5rs145204276 indel polymorphism with cancer risk under allelic model (delvs. ins) (OR: 0.98; 95%CI: 0.8024; 1.1941; p: 0.83;I2 : 94%); a recessive model (del/delvs. del/ins+ ins/ins) (OR: 1.09; 95%CI: 0.7822; 1.5251; p: 0.60;I2 : 88%); a dominant model (del/del+ del/insvs. ins/ins) (OR: 0.95; 95%CI: 0.7571; 1.2016; p: 0.69;I2 : 92%), an over-dominant model ( del/insvs. del/del+ ins/ins) (OR: 0.93; 95%CI: 0.8199; 1.0549; p: 0.26;I2 : 71%); a homozygote contrast model (del/delvs. ins/ins) (OR: 1.06; 95%CI: 0.6964; 1.6162; p: 0.78;I2 : 92%); an additive model (del/delvs. ins/del) (OR: 1.15; 95%CI: 0.9055; 1.4682; p: 0.25;I2 : 74%) and a heterozygote contrast model (del/ins vs. ins/ins) (OR: 0.94; 95%CI: 0.7744; 1.1403; p: 0.53;I2 : 87%) (Figure 2).
Furthermore, in the subgroup analysis based on cancer types, the rs145204276 indel polymorphism was associated with a lower risk of gastric cancers in the population in different genetic models; allelic model (del vs. ins) (OR: 0.78; 95%CI: 0.6916; 0.8701; p: 0.00;I2 : 40%); a recessive model (del/delvs. del/ins+ ins/ins) (OR: 0.73; 95%CI: 0.5565; 0.9603; p: 0.02;I2 : 00%); a dominant model (del/del+ del/insvs. ins/ins) (OR: 0.73; 95%CI: 0.6278; 0.8404; p: 0.00;I2 : 29%); an over-dominant model ( del/insvs . del/del+ ins/ins) (OR: 0.79; 95%CI: 0.6809; 0.9161; p: 0.00;I2 : 45%); a homozygote contrast model (del/delvs. ins/ins) (OR: 0.64; 95%CI: 0.4861; 0.8529; p: 0.00;I2 : 38%) and a heterozygote contrast model (del/ins vs. ins/ins) (OR: 0.75; 95%CI: 0.6394; 0.8683; p: 0.00;I2 : 40%). Furthermore, in the subgroup analysis based on the source of control, we did not find any significant association between the polymorphism and the subgroup investigations (Table 2).